title: Quinupristin/dalfopristin-induced Sweet's syndrome.
abstract: Quinupristin/Dalfopristin is a new combination of streptogramin antibiotics designed specifically to treat clinically significant infections due to Vancomycin-resistant Enterococcus Faecium. Sweet's syndrome is characterized by painful skin plaques, which is associated with dermal neutrophilic infiltration, fever and peripheral blood leukocytosis. Drug-induced Sweet's syndrome has a temporal relationship between drug ingestion, clinical presentation and the temporally-related resolution of lesions following drug withdrawal or on treatment with systemic corticosteroids. A 63-year-old woman received Quinupristin/Dalfopristin for acute pyelonephritis developed fever, arthralgia, vomiting, and painful erythematous skin plaques. A skin biopsy showed neutrophilic dermatosis, and there was rapid resolution of the symptoms and cutaneous lesions after discontinuation of Quinupristin/Dalfopristin, consistent with drug-induced Sweet's syndrome. To date, there has been no reported case of Sweet's syndrome associated with the use of Quinupristin/Dalfopristin.
authors: Department of Internal Medicine, School of Medicine, Kyung Hee University, Seoul, Korea.
authors: Hye Sook
authors: HS
authors: Choi
authors: Hee Jin
authors: HJ
authors: Kim
authors: Tae Hee
authors: TH
authors: Lee
authors: Sang Hoon
authors: SH
authors: Lee
authors: Tae Won
authors: TW
authors: Lee
authors: Chun Gyoo
authors: CG
authors: Ihm
authors: Myung Jae
authors: MJ
authors: Kim
mesh_terms: D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D008875:Middle Aged; D012867:Skin / Q000187:drug effects / Q000473:pathology; D016463:Sweet Syndrome / Q000139:chemically induced* / Q000473:pathology; D014769:Virginiamycin / Q000008:administration & dosage / Q000009:adverse effects* / Q000031:analogs & derivatives*
chemical_list: D000900:Anti-Bacterial Agents; D014769:Virginiamycin; C113825:quinupristin; C113826:dalfopristin